#EASL

Here is the link to the latest EASL summary of optimum Hep C treatment options for the various genotypes.

Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver include treatments that benefit a wider...

Highlights from the the spring meeting of EASL’s 50th International Liver Congress

NAFLD, liver cancer and new noninvasive liver tests will get more of the research spotlight than ever before.

12 weeks of Merck’s grazoprevir and elbasvir cured hepatitis C in 99 percent of people with genotype 1 of the virus and advanced kidney...

The European Association for the Study of the Liver has issued revised guidelines for the treatment of hepatitis C.

Curing hepatitis C reduces central fatigue, which is weakness originating in the central nervous system.

Twenty-four weeks of Gilead Sciences’ Sovaldi and ribavirin boasted high cure rates among people with genotype 4 of hep C in a recent trial.

Interferon, along with depression and fatigue, is an independent variable that dampens the experience of hepatitis C treatment.

AbbVie’s ’3-D’ regimen has had nearly perfect preliminary results in curing people with recurrent geno 1 of hep C post-liver transplant.